Latest Articles about MDVN

Bayer's Xofigo Cleared in the US - Analyst Blog

Zacks Equity Research — Fri, 17 May 2013 02:30:48 Z

Bayer 's ( BAYRY ) HealthCare segment recently received encouraging news as the US Food and Drug Administration (FDA) approved its oncology drug Xofigo (radium 223 dichloride). Xofigo was

Medivation Loss Narrower Than Expected - Analyst Blog

Zacks Equity Research — Mon, 13 May 2013 17:40:01 Z

Medivation Inc. ( MDVN ) reported a first-quarter loss of 36 cents per share, narrower than the Zacks Consensus Estimate of a loss of 41 cents per share. However, the company recorded

After-Hours Earnings Report for May 9, 2013 : PCLN, PSA, NVDA, CFN, AGO, MDVN, GXP, SLXP, AL, BID, MDRX, SF

NASDAQ.com News — Thu, 09 May 2013 22:00:04 Z

The following companies are expected to report earnings after hours on 05/09/2013. Visit our Earnings Calendar for a full list of expected earnings releases. priceline.com Incorporated (

Pharmacyclics Inc. (PCYC): Today's Most Compelling Stock Buy

David Moenning — Tue, 07 May 2013 21:53:41 Z

SoTM Bull's Eye Report - Today's Most Compelling Buy Tuesday, May 7, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the

Eylea Drives Earnings at Regeneron - Analyst Blog

Zacks Equity Research — Fri, 03 May 2013 22:35:14 Z

Regeneron Pharmaceuticals Inc .'s ( REGN ) first quarter 2013 earnings (excluding special items but including stock-based compensation) of $1.30 per share breezed past the Zacks Consensus

Narrower-Than-Expected Loss at Incyte - Analyst Blog

Zacks Equity Research — Fri, 03 May 2013 22:31:00 Z

Incyte Corporation ( INCY ) reported a loss of 12 cents per share in the first quarter of 2013, narrower than the loss of 13 cents hinted by the Zacks Consensus Estimate. The company's

Wider-Than-Expected Loss at Pharmacyclics - Analyst Blog

Zacks Equity Research — Thu, 02 May 2013 22:26:47 Z

Pharmacyclics Inc. 's ( PCYC ) first quarter 2013 loss of 73 cents per share was wider than the year-ago loss of 19 cents and the loss of 8 cents hinted at by the Zacks Consensus Estimate.

Polycyclics Inc. (PCYC): Today's Most Compelling Stock Pick

David Moenning — Fri, 26 Apr 2013 23:20:21 Z

SoTM Bull's Eye Report - Today's Most Compelling Buy Friday, April 26, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the

Aragon Pharma's ARN-509 Is No Near-Term Threat to Medivation

David Miller — Tue, 23 Apr 2013 19:55:00 Z

If I don't miss my guess, Medivation ( MDVN ) shares will come under pressure today based upon an 8-K it filed on Monday. The decline, if it happens, reflects a basic lack of understanding of

How the bulls are trading Medivation

David Russell — Mon, 22 Apr 2013 21:20:11 Z

One investor is adjusting a bullish position in Medivation, whose shares have been consolidating after a screaming rally last year. optionMONSTER's Heat Seeker monitoring program detected the

Astellas/MDVN Provide Update on Xtandi - Analyst Blog

Zacks Equity Research — Wed, 03 Apr 2013 01:24:15 Z

Astellas Pharma Inc. ( ALPMY ) and partner Medivation, Inc. ( MDVN ) recently announced that the companies have established an updated interim analysis plan for an ongoing phase III

Good News for Nymox's Pipeline - Analyst Blog

Zacks Equity Research — Fri, 22 Mar 2013 02:23:03 Z

Positive news flowed in at Nymox Pharmaceutical Corporation ( NYMX ) recently when the Independent Data Monitoring Committee (IDMC) reported the third positive analysis of safety data from

Merck-Luminex' Alzheimer's Collaboration - Analyst Blog

Zacks Equity Research — Wed, 20 Mar 2013 00:47:42 Z

Merck ( MRK ) recently entered into an agreement with Luminex Corporation ( LMNX ) for the development of a companion diagnostic device that will be used to screen patients for

Pluristem & UTHR Progress with PLX-PAD - Analyst Blog

Zacks Equity Research — Tue, 05 Mar 2013 03:25:01 Z

Israel-based Pluristem Therapeutics Inc. ( PSTI ) recently announced that partner United Therapeutics Corporation ( UTHR ) intends to commence a phase I study in Australia using

Medivation Beats 4Q Expectations - Analyst Blog

Zacks Equity Research — Fri, 01 Mar 2013 19:00:01 Z

Medivation Inc. ( MDVN ) reported a fourth-quarter loss of 43 cents per share, narrower than the Zacks Consensus Estimate of a loss of 51 cents per share but well above the year-ago loss of